All Outputs (5)

PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies (2013)
Journal Article
Khan, G., Denniss, F., Mills, K. I., Guinn, B.-A., & Pulford, K. (2013). PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies. Genetic Syndromes and Gene Therapy, 04(09), Article 186. https://doi.org/10.4172/2157-7412.1000186

In general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in... Read More about PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies.

An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide (2013)
Journal Article
Hardwick, N., Buchan, S., Ingram, W., Khan, G., Vittes, G., Rice, J., Pulford, K., Mufti, G., Stevenson, F., & Guinn, B. A. (2013). An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immunology Research, 13(3), 16-26. https://doi.org/10.1158/1424-9634.DCL-16.13.3

We have previously identified the novel Cancer/Testis antigen PASD1 by immunoscreening a testis library with pooled acute myeloid leukemia (AML) patient sera. To develop a cytotoxic T lymphocyte (CTL)-inducing vaccine, we have now investigated the ca... Read More about An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation (2013)
Journal Article
Liberante, F. G., Pellagatti, A., Boncheva, V., Bowen, D. T., Mills, K. I., Boultwood, J., & Guinn, B. A. (2013). High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation. British journal of haematology, 162(2), 282-285. https://doi.org/10.1111/bjh.12352

New targets for the immunotherapy of colon cancer - Does reactive disease hold the answer (2013)
Journal Article
Boncheva, V., Bonney, S. A., Brooks, S. E., Tangney, M., O'Sullivan, G., Mirnezami, A., & Guinn, B. A. (2013). New targets for the immunotherapy of colon cancer - Does reactive disease hold the answer. Cancer Gene Therapy, 20(3), 157-168. https://doi.org/10.1038/cgt.2013.5

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in both men and women, posing a serious demographic and economic burden worldwide. In the United Kingdom, CRC affects 1 in every 20 people and it is often detected once well establ... Read More about New targets for the immunotherapy of colon cancer - Does reactive disease hold the answer.

Innovative evolution of cancer gene and cellular therapies (2013)
Journal Article
Lam, P., Khan, G., Stripecke, R., Hui, K. M., Kasahara, N., Peng, K. W., & Guinn, B. A. (2013). Innovative evolution of cancer gene and cellular therapies. Cancer Gene Therapy, 20(3), 141-149. https://doi.org/10.1038/cgt.2012.93

We provide an overview of the latest developments in cancer gene therapy - from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emerg... Read More about Innovative evolution of cancer gene and cellular therapies.